XJZY(SZ:002332)2021-04-27 16:00Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2020, representing a year-on-year growth of 15%[7]. - The net profit attributable to shareholders was 250 million RMB, an increase of 20% compared to the previous year[7]. - The company's operating revenue for 2020 was ¥4,018,872,772.40, an increase of 8.37% compared to ¥3,708,545,530.97 in 2019[27]. - Net profit attributable to shareholders for 2020 was ¥504,509,427.41, representing a growth of 22.94% from ¥410,368,585.97 in 2019[27]. - The total profit reached 621.25 million yuan, up 17.82% year-on-year, while net profit attributable to shareholders was 504.51 million yuan, reflecting a 22.94% increase[65]. - The company achieved a revenue of 4,018.87 million CNY, representing a year-on-year growth of 8.37%[44]. - The net cash flow from operating activities increased by 51.83% to ¥789,233,376.74 from ¥519,805,113.67 in 2019[27]. - The company reported a total sales volume of 400,196.45 million yuan in 2020, an increase of 8.27% from 2019[82]. Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares, based on a total share capital of 989,204,866 shares as of December 31, 2020[7]. - In 2020, the company distributed cash dividends totaling ¥148,380,729.90, which represents 29.41% of the net profit attributable to shareholders of the listed company[164]. - The net profit attributable to shareholders for 2020 was ¥504,509,427.41, with a profit distribution base of 989,204,866 shares, resulting in a cash dividend of ¥1.5 per 10 shares[167]. - The total distributable profit for the year was ¥931,501,460.58, with cash dividends accounting for 100% of the profit distribution[167]. - The company executed a cash dividend of 1 CNY per 10 shares for the 2019 fiscal year, amounting to approximately 91.62 million CNY[163]. - The company issued a cash dividend of 0.65 CNY per 10 shares for the 2018 fiscal year, totaling approximately 59.55 million CNY[163]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its R&D capabilities to drive future growth[7]. - New product launches are expected to contribute significantly to revenue in the upcoming fiscal year, with a target of introducing at least 5 new drugs[7]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[7]. - The company aims to achieve a revenue growth target of 20% for the next fiscal year, driven by new product introductions and market expansion strategies[7]. - The company is actively expanding into international markets, enhancing its market share in the global steroid industry[44]. - The company aims to enhance market share in the raw material drug sales by coordinating various departments and responding quickly to market demands, focusing on high-end market expansion in Latin America, the Middle East, and Russia[142]. Research and Development - The company is investing heavily in technology development, with a budget allocation of 100 million RMB for R&D in 2021[7]. - The company received 7 national invention patents during the reporting period, bringing the total to 42 authorized patents, enhancing its R&D capabilities[58]. - Research and development investment amounted to ¥208,385,907.97 in 2020, representing a 1.89% increase from ¥204,521,925.83 in 2019[101]. - The number of R&D personnel increased to 448, a 4.19% rise from 430 in the previous year[101]. - Continuous improvement of R&D capabilities is emphasized, with a focus on consistency evaluation and innovative R&D projects, aiming to establish a stable performance in the production line and develop a steroid drug API platform[143]. Risk Management - The company has identified key risks including industry policy changes, drug price reductions, and R&D risks, which may impact future performance[7]. - The company is addressing risks related to industry policy changes and drug price reductions by closely monitoring industry trends and enhancing innovative product development[149]. - The company faces quality control risks due to new regulations and standards, necessitating improved coordination among research, production, and quality departments[150]. - The company recognizes the risk of talent shortages as it expands and integrates acquisitions, emphasizing the need for skilled professionals with international perspectives[151]. Operational Efficiency - The company has a strong emphasis on internal management and cost control, resulting in significant operational efficiency improvements[44]. - The company is committed to compliance production and comprehensive cost control, establishing a new responsibility assessment system to enhance operational efficiency and production capacity[144]. - Quality management systems are being enhanced to meet international standards, with ongoing efforts in the registration of international raw material drug varieties and compliance with GMP standards[145]. - The implementation of an integrated management system through the Kingdee ERP project aims to optimize business processes and improve operational efficiency across various departments[146]. Subsidiaries and Investments - The company established two new subsidiaries, Jiaxing Pharmaceutical Company and Hangzhou Technology Innovation Company, with an investment of 3.5 million yuan each, acquiring a 70% stake in both[192]. - The subsidiary Taizhou Xianju Pharmaceutical Co., Ltd. reported a net profit of ¥76,404,900, contributing over 10% to the company's net profit[127]. - The company has invested in several overseas subsidiaries, with total foreign equity assets amounting to CNY 30.99 million for Newchem and CNY 28.23 million for Effechem, contributing positively to revenue[53]. Compliance and Governance - The company has committed to strict adherence to share lock-up agreements for its major shareholders following the non-public issuance of A-shares[171]. - The company has a commitment from its actual controller and major shareholders to fulfill their obligations during the reporting period[168]. - The company has not faced any major litigation or arbitration matters during the reporting period[198]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 20 years, with an audit fee of 1.85 million yuan for the current period[193].